Divesiran Hits Phase 2 PV Endpoint

Company: Silence Therapeutics · Event Type: Clinical/Regulatory Signal · Product/Asset: divesiran · Subject: Polycythemia Vera · Event Date: August 10, 2026 Summary Silence Therapeutics reported that divesiran met the randomized Phase 2 SANRECO primary endpoint in phlebotomy-dependent polycythemia vera (PV). Clinical response occurred in 88%…